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Abstract
mTOR inhibitors are used clinically to treat renal cancer but are not curative. Here we show that autophagy is a resistance
mechanism of human renal cell carcinoma (RCC) cell lines to mTOR inhibitors. RCC cell lines have high basal autophagy that
is required for survival to mTOR inhibition. In RCC4 cells, inhibition of mTOR with CCI-779 stimulates autophagy and
eliminates RIP kinases (RIPKs) and this is blocked by autophagy inhibition, which induces RIPK- and ROS-dependent
necroptosis in vitro and suppresses xenograft growth. Autophagy of mitochondria is required for cell survival since mTOR
inhibition turns off Nrf2 antioxidant defense. Thus, coordinate mTOR and autophagy inhibition leads to an imbalance
between ROS production and defense, causing necroptosis that may enhance cancer treatment efficacy.
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Introduction
Macroautophagy (autophagy) is a process whereby cellular
components such as proteins and organelles are captured within
autophagosomes, and are delivered to the lysosomes for degrada-
tion [1]. Autophagy is activated by starvation, enabling cellular
and mammalian viability by providing an internal source of
building blocks for macromolecular synthesis. This sustains
biosynthetic and energy requirements during interruptions in
nutrient availability [2,3,4,5]. Cellular damage also activates
autophagy, which promotes cell survival by preventing accumu-
lation of damaged proteins and organelles, particularly mitochon-
dria that are a source of oxidative stress [6,7]. These intracellular
recycling and garbage disposal roles of autophagy provide cells
with the inherent flexibility to cope with periods of deprivation
while limiting oxidative stress. Although autophagy is important
for the function and survival of normal cells, it is also utilized by
tumor cells and may be therapeutically counterproductive
[5,8,9,10,11].
Metabolic stress due to oxygen, nutrient and growth factor
deprivation is common in tumors due to insufficient vasculariza-
tion, and autophagy is activated in tumor cells in hypoxic regions
to support survival [12,13,14]. Tumor cells in oxygen-deprived
hypoxic regions are more resistant to treatment and this
autophagy-conferred survival advantage has led to the realization
that autophagy inhibitors may be useful to improve cancer therapy
[15,16]. Moreover, cytotoxic and targeted cancer therapeutics
induce autophagy, either by infliction of stress and cellular damage
or by inhibition of signaling pathways mimicking deprivation
[5,15]. The potential of environmental and therapeutic autophagy
induction to limit treatment effectiveness remains to be addressed.
Cells respond to growth signals in their environment through
the phosphoinositide 3-kinase (PI3K) pathway and regulation of
the serine-threonine kinase mTOR. mTOR promotes cell growth
in response to nutrient and growth factor availability, while
suppressing autophagy [17]. In nutrient and growth factor replete
conditions, the PI3K pathway activates mTOR through the
mTORC1 complex that binds, phosphorylates and inhibits key
autophagy machinery components required to initiate autophago-
some formation [18,19,20,21]. Tumor cells commonly take
advantage of the cell growth-promoting function of the PI3K
pathway by acquiring mutations that result in its constitutive
activation [17]. As such, inhibitors of the PI3K pathway are
potentially useful for restricting tumor growth, although they also
activate autophagy. It is unclear, however, if this induction of
autophagy is a mechanism of resistance by increasing tumor cell
stress tolerance.
mTOR inhibitors include both allosteric (rapamycin/sirolimus,
and other rapalogs such as temsirolimus and everolimus) and
ATP-competitive mechanistic classes. Both temsirolimus and
everolimus have shown efficacy in the treatment of renal cancer
and are approved by the Food and Drug Administration (FDA) to
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treat RCC [22,23]. In the first line setting, temsirolimus improves
overall survival in RCC patients with metastatic disease. Unfor-
tunately, all patients eventually relapse, contributing to the dismal
prognosis of this devastating disease. It is expected that most
targeted therapeutics, including temsirolimus, will require combi-
nation therapy for improved therapeutic outcome, necessitating
identification of synthetic lethal pathways.
If autophagy induction by mTOR inhibitors promotes tumor
cell survival, then combination treatment with an autophagy
inhibitor may be expected to promote tumor cell death [11]. One
tractable, small molecule approach to autophagy inhibition is the
lysosomotropic anti-malaria drug CQ and its analogues. CQ
prevents lysosome acidification and thereby the degradation of the
products of autophagy, resulting in autophagolysosome accumu-
lation. In a mouse model of c-Myc-driven lymphoma, a CQ
analogue hydroxychloroquine (HCQ) promotes tumor cell death
by either p53 activation or alkylating agents [24]. In mouse models
for ataxia telangiectasia and Burkitt’s lymphoma, CQ suppresses
spontaneous tumorigenesis [25]. CQ also has antitumor activity in
mouse models of BRC-Abl leukemia [26] and in combination with
the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) in a
mouse model and in human samples of CML [27]. In human solid
tumor xenografts, CQ inhibits tumor growth as a single agent in
pancreatic cancer, and in combination with PI3K pathway
inhibitors in glioma or with mTOR inhibitors in tuberous sclerosis
complex (TSC)-deficient tumors [28,29,30]. These preclinical
studies support the approach of autophagy inhibition in cancer
therapy [15,16]. One major limitation is the unknown mechanism
by which autophagy inhibition promotes cancer cell death,
particularly in combination with PI3K pathway inhibition, and
what defines cancer susceptibility to autophagy inhibition.
Since the mTOR inhibitor temsirolimus (Torisel or CCI-779)
has efficacy in RCC [23] and promotes autophagy [31,32], we
assessed the functional consequences of coordinate autophagy
inhibition with CQ in human RCC cell lines. We found that
mTOR inhibition induced selective autophagy of mitochondria
(mitophagy) and eliminated RIPKs, the master regulators of
necroptosis. Addition of CQ promoted cell death by preventing
autophagy, causing RIPK- and ROS-mediated necroptosis. As
mTOR inhibition blocked Nrf2 nuclear translocation and
antioxidant defense by activating GSK3b, RCC cell lines were
sensitized to inhibition of autophagy with CQ and the subsequent
ROS production. Thus, autophagy is a cancer therapy survival
mechanism to RIPK-dependent necroptosis in the setting of
cancer therapy. These findings support clinical assessment of
autophagy inhibition to augment the activity of mTOR inhibitors
in RCC where Nrf2, autophagy, and RIPK elimination are
required for survival.
Results
Human RCC lines have high levels of basal autophagy
Human RCCs have high basal autophagy as indicated by
processing of LC3-I to the autophagosome localized LC3-II form
(Figure 1A) and 30–60% LC3 punctation (Figure S1A) that are
substantially higher than the 1–5% level in normal kidney cell lines
[14]. All cell lines display 100% LC3 punctation when treated with
CQ (Figure S1A). In RCC4, high basal autophagy occurred despite
presence of active PI3K/mTOR signaling (phosphorylation S6,
(Figure 1D). CQ caused accumulation of LC3 puncta and LC3-II
indicating high flux through the autophagy pathway and that
autophagy was blocked (Figure 1B–D). The mTOR inhibitor CCI-
779 blocked phosphorylation of S6, indicating that mTOR kinase
activity was inhibited (Figure 1D). CQ partially rescued this at
9 hours, which may result from perturbation of lysosomes. CCI-779
increased turnover and clearance of LC3 positive autophagosomes
and LC3-II by Western blot (Figure 1D) indicating increased
autophagic flux, which was blocked with CQ (Figure 1B–C).
Knockdown of the essential autophagy gene product Atg7 with 2
independent shRNAs impaired growth in RCC4 cells as compared
to two control hairpins (Figure 1E and 1F). Thus, RCC cells have
high basal autophagy that was required for growth, stimulated by
CCI-779, blocked by CQ and consistent with autophagy addiction
commonly found in cancer cell lines [4,29,33]
Cytotoxicity of coordinate mTOR and autophagy
inhibition
To test if mTOR inhibitors promote survival by autophagy,
RCC4 was treated with allosteric (CCI-779), or catalytic (Torin1),
mTOR inhibitors alone or in combination with CQ. CQ, CCI-
779 and Torin1 were predominantly cytostatic, but either mTOR
inhibitor was cytotoxic when combined with CQ (Figure 2A, 2B,
S2A). After 5 days, cells recovered without drugs and clonogenic
potential was assessed. CQ, CCI-779 and Torin1 had no effect on
recoverable growth, while the combination of CQ with CCI-779
or Torin1 prevented clonogenic survival (Figure 2C). The
combination of CQ and CCI-779 was equally cytotoxic to
VHL-mutant RCC cell lines (RCC4, A498) and to these cell lines
that had VHL reexpressed, suggesting that sensitivity was HIF-
independent (Figure S1B, and Movies S1, S2, S3, S4, S5, S6, S7,
S8, S9, S10, S11, S12, S13, S14, S15, and S16). Knockdown of
Atg7 with 2 different shRNAs also sensitized RCC4 cells to CCI-
779, indicating that autophagy was responsible for resistance to
mTOR inhibition (Figure 2D and S2B). To determine if the
combination of CQ and CCI-779 could suppress tumor growth,
RCC4 xenografts were examined. Tumors continued to grow
when treated with vehicle, CQ or CCI-779, while the combination
of CQ and CCI-779 prevented tumor growth (Figure 2E).
Importantly, mice appeared healthy during of the treatment with
no observable weight loss or change in behavior indicating that the
treatment was well tolerated. Thus, autophagy is a resistance
mechanism to CCI-779 that could be reversed by genetic blockade
of autophagy initiation or pharmacologic blockade of cargo
degradation.
mTOR inhibition and CQ induce RIPK -dependent
necroptosis
To determine the type of cell death induced by the combination
of CQ and CCI-779, RCC4 cells were examined for cleavage of
the apoptosis marker caspase-3. Minimal active caspase-3 was
detected in CQ and CCI-779 treated cells when compared to a
staurosporine treated control (Figure S3A). Addition of the broad
spectrum caspase inhibitor Q-VD-OPh failed to rescue cell death
by the combination of CQ and CCI-779 in a clonogenic assay,
suggesting that RCC cells were not dying by apoptosis.
When examined by electron microscopy, CQ and CCI treated
cells displayed signs of plasma membrane rupture indicative of a
necrotic phenotype (data not shown). Death may also occur by a
programmed form of necrosis, necroptosis, which requires RIPK1
and RIPK3 activated by death receptors [34] or death receptor-
independent mechanisms [35]. To assess if CQ and CCI-779
induced necroptosis, human RCCs were treated with CQ and
CCI-779 in the absence and presence of the specific RIPK1 and
necroptosis inhibitor Necrostatin-1 (Nec1) [36]. Nec1 alone had
no effect, but dramatically restored clonogenic survival by the
combination of CQ and CCI-779 in 4 of 7 RCC cell lines
(Figure 3A). Knockdown of RIPK3 in RCC4 (Figure 3C) also
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suppressed cell death (Figure 3B and S3C) and enhanced
clonogenic survival (Figure 3D), confirming cell death by CQ
and CCI-779 was RIPK-dependent necroptosis. RCC4 cells failed
to cleave caspase-8 in response to CQ and CCI further supporting
necroptotic cell death (Figure S3D). Similarly, RCC4 cells
remained viable in response to the combination of TNF-a and
Z-VAD-FMK further supporting the conclusion that RCC4 cells
are defective of necroptosis induced by TNF-a, (Figure S3E)
possibly due to defective TNF-a signaling. This was in stark
contrast to control FADD-deficient Jurkat cells, which died in
response to TNF-a and Z-VAD-FMK (Figure S3E).
Mitochondrial ROS production causes necroptosis
Necroptosis is often associated with mitochondrial ROS
production [34,37,38] suggesting that combining CQ and CCI-
779 may cause lethal mismanagement of oxidative stress. CCI-779
alone induced ROS as indicated by the ROS sensor DCF-DA
(Figure 4A) and by increased MitoSOXTM Red superoxide
detector staining of mitochondria (Figure S4A). ROS production
was elevated when CCI-779 was combined with CQ (Figure 4A
and S4A). To determine if ROS production by CCI-779 and CQ
was required for cell death, we tested for rescue of cell death by the
ROS scavenger, N-Acetyl Cysteine (NAC). NAC, but not ROS
scavenger-inactive N-Acetyl Alanine (NAA), inhibited necroptosis
and enabled clonogenic survival to the combination of CCI-779
and CQ or Bafilomycin A1 (BAF) that prevents maturation of
autophagic vacuoles [39] (Figure 4B–C and S4B–F). Since mTOR
inhibition suppresses glycolysis [40,41] and presumably produc-
tion of the mitochondrial substrate pyruvate, we tested if
supplementation with methyl-pyruvate (MP) prevented cell death.
Figure 1. The human renal cancer cell line RCC4 has high basal autophagy. (A) LC3 immunoblotting in human RCC cell lines. Human RCC
cells have high basal autophagy as indicated by the presence of the lipidated-conjugate, LC3-II, under normal culture conditions. (B) Quantitation of
LC3 punctation in RCC4 under a 9 hour drug treatment. 40 mM CQ caused accumulation of autophagosomes above basal levels (*p = 3.0561025)
while 40 mM CCI-779 caused clearance of autophagosomes after a 9 hour drug treatment (**p = 0.0013). Error bars represent 6 standard deviation
(S.D.). (C) LC3 immunostaining of RCC4. Representative photos of Figure 1B. Scale bar = 10 microns. (D) Western blot of RCC4 showing accumulation
of LC3-II with CQ and clearance of LC3-II with CCI-779 at 9, 12 and 16 hours. S6 lost phosphorylation with CCI-779 treatment while total S6 level
remained the same. (E) Western blot showing knockdown of Atg7 in RCC4 after expression of two shRNAs targeted against Atg7 (shatg7 #1, shatg7
#2), as compared to control siRNA’s, shRfps or shLUC. (F) Viability graph showing impaired viability and cell growth after atg7 knockdown. Error bars
represent 6 standard deviation (S.D.). (*p = 0.030 **p= 0.002).
doi:10.1371/journal.pone.0041831.g001
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Indeed, MP rescued cell death and clonogenic survival with CCI-
779 and CQ or BAF (Figure 4B–C and S4B–C), suggesting that
mitochondria are substrate-limited and that supplementing
mitochondrial substrates supports normal respiration and survival.
mTOR inhibition elevates oxidative metabolism and
demand for substrates
To examine the impact of CCI-779 and glycolysis inhibition on
cellular metabolism, relative pool sizes of glycolytic and tricar-
boxylic acid (TCA) cycle intermediates were analyzed by LC-MS.
Pool size measurements showed accumulation of phosphoenol-
pyruvate (PEP) and depletion of pyruvate and other TCA cycle
metabolites in RCC4 cells with CCI-779 or the combination of
CQ and CCI-779 (Figure 4D). This suggests that CCI-779 inhibits
glycolysis upstream of pyruvate.
As glycolysis inhibition can cause compensatory upregulation of
mitochondrial respiration leading to increased ROS production
[42], we examined if mTOR inhibition increased mitochondrial
function, and thus mitochondrial oxidative phosphorylation by
measuring the oxygen consumption rate (OCR), which is a direct
readout of mitochondrial function. OCR was low in RCC4 cells,
consistent with high glycolytic metabolism, and the addition of
CCI-779 increased OCR, suggesting that blocking glycolysis
through mTOR inhibition switched cellular metabolism more
toward oxidative phosphorylation (Figure 4E). This suggested that
CCI-779 and glycolysis inhibition caused a compensatory
upregulation of mitochondrial respiration, possibly as an alterna-
tive ATP source, which elevated mitochondrial substrate demand.
This increase in OCR was augmented by addition of MP, while
the ROS scavenger NAC had no effect (Figure 4E), indicating that
MP directly supported mitochondrial respiration and survival
primarily by overcoming TCA substrate depletion.
mTOR inhibition induces mitophagy that is blocked by
CQ
Combination of CQ and CCI-779 induced cell death that was
reversed by inhibition of RIPKs, NAC or MP, suggesting that it
resulted from mismanagement of mitochondrial metabolic func-
tion. To investigate this, mitochondrial morphology was examined
by electron microscopy. Mitochondria appeared normal with CQ
alone, and CCI-779 caused mitochondrial fragmentation that
persisted in combination with CQ (Figure S5A). Fragmented
Mitochondrial were not sequestered in lysosomes or autophago-
somes implying that they might be the source of ROS production.
To assess if this was associated with mitochondrial dysfunction,
mitochondrial membrane potential was measured with the
potential dependent dye Mitotracker Red in comparison to the
mitochondrial marker Tom20. CCI-779, and to a much greater
extent CQ and CCI-779, disrupted membrane potential and
Figure 2. Coordinate autophagy and mTOR inhibition is cytotoxic to human RCC. (A) Viability graph of RCC4 cells treated with 10 mM or
20 mM CQ, 20 mM CCI-779 or combination of CQ and CCI-779. After 7 days, cells treated with CQ and CCI-779 as single agents were viable and showed
growth arrest. The combination of 20 mM CQ with 20 mM CCI-779 reduced viability to 10%. (*p = 0.033, +p= 0.038,**p= 0.016,++p= 0.028.) (B) Viability
graph of 20 mM CQ alone, 250 nM or 500 nM Torin1 or the combination of CQ and Torin1. After 7 days CQ treated cells were viable, Torin1 treated
cells were 60% viable, and the combination of CQ and Torin1 were 20% viable (20 mM CQ+250 nM Torin1) and 10% viable (20 mM CQ+500 nM
Torin1). Viability was measured by trypan blue exclusion and is relative to day 0. Error bars represent 6 S.D. (*p = 0.020,+p= 0.036,**0.016, (C)
Clonogenic survival assay showing that the combination of CQ and CCI-779 or CQ and Torin1 severely impairs long term survival. (D) % viability of
knockdown cells under 40 mM CQ, 40 mM CCI-779 or combination of CQ and CCI-779 for 18 hours. CCI-779 alone with atg7 knockdown induced
significant cell death (*p = 0.002 **p= 2.0161024). Error bars represent 6 S.D. (E). RCC4 cells were grown as xenografts in nude mice. When tumors
reached 150 mm3, mice were injected with vehicle (dark blue), CQ (red), CCI-779 (yellow) or combination of CQ and CCI-779 (light blue). Combination
of CQ and CCI-779 prevented further tumor growth as compared to CQ alone (p = 0.011) or CCI-779 (p = 0.003). Arrows indicate days that CQ and CCI-
779 were injected. Error bars are 6 s.e.m.
doi:10.1371/journal.pone.0041831.g002
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fragmented mitochondria indicating mitochondrial dysfunction
(Figure 4F).
Depolarized, fragmented mitochondria are degraded by
mitophagy. To determine if mTOR inhibition induced mito-
phagy, RCC4 cells were transfected with the mitophagy marker
mCherry-Parkin, which translocates to depolarized mitochondria
and serves as a signal for mitochondrial degradation via autophagy
[43]. CCI-779 induced Parkin translocation that was increased by
the combination of CQ and CCI-779 (Figure 4G–H). This
suggests that CQ blocked mitophagy, preventing clearance of
ROS-producing mitochondria resulting from mTOR inhibition.
Mitochondria are required for necroptosis
As CCI-799 promotes mitochondrial elimination by mitophagy,
and blocking mitophagy with CQ leads to mitochondrial ROS
production and necroptosis, we examined whether blocking
mitochondrial respiration and promoting mitophagy before drug
treatment would prevent necroptosis. Uncoupling mitochondria
with carbonyl cyanide m-chlorophenylhydrazone (CCCP) causes
depolarization, Parkin translocation and elimination of most but
not all cellular mitochondria by mitophagy (Figure S5C–D)
[44,45]. Pretreatment of RCC4 cells with CCCP prevented
necroptosis by CQ and CCI-779 and restored clonogenic survival
(Figure 4I–J and S5B). CCI-779 caused a profound reduction of
RIPK1, RIPK3 and the mitochondrial marker Tom20 which was
prevented by CQ (Figure 4I). Loss of RIPK1 and RIPK3 was
blocked by the proteasome inhibitor epoxomicin indicating
degradation by the ubiquitin proteasome system. CCI-779 also
caused cleavage of the inner mitochondrial protein Opa1,
indicative of mitochondrial fragmentation (Figure 4K). This
suggested that elimination of RIPKs through both the ubiquitin
proteasome system and elimination of mitochondria by mitophagy
is a resistance mechanism to mTOR inhibition that prevents
ROS- and RIPK-mediated necroptosis, which is reversed by
autophagy/mitophagy inhibition with CQ.
mTOR inhibition blocks Nrf2 nuclear translocation and
antioxidant defense
If mitochondrial ROS production and RIPK activation is the
mechanism by which CQ and CCI-779 promote necroptosis, we
questioned why this was not prevented by antioxidant defense
pathways. Nrf2 is a critical transcription factor controlling
expression of antioxidant defense genes [46]. Nrf2 binds Keap1,
a member of the Keap1-Cullin3-E3 ubiquitin ligase complex that
targets Nrf2 for degradation in proteasomes [47]. Nrf2 is activated
by the adaptor protein p62 that binds and inhibits Keap1,
releasing and stabilizing Nrf2 causing its nuclear translocation and
antioxidant response [48,49]. In RCC4 cells, ectopically expressed
RFP-Nrf2 was present in the nucleus and cytoplasm of approx-
imately one third of RCC4 cells under normal growth conditions,
Figure 3. Cell death induced by autophagy and mTOR inhibition is RIPK-dependent necroptosis. (A) Clonogenic survival assay showing
Nec1 pretreatment rescues clonogenic survival. RCC cells were pretreated for one hour with Necrostatin1 (Nec1) followed by the addition of CQ, CCI-
779 or combination of CQ and CCI-779 to the media. After 18 hours media was changed to normal culture media and cells were allowed to recover
for 5 days. In 4 of 7 RCC cell lines (RCC4, A498, ACHN, 786O), Nec1 pretreatment rescued clonogenic survival from CQ and CCI. (B) Viability graph
showing that siRNA knockdown of RIPK3 in RCC4 prevented cell death induced by an 18 hour drug treatment of combination of CQ and CCI-779 as
compared to siRNA control siLamin (*p= 0.007). Error bars represent 6 S.D. (C) Western blots of RNA knockdown of RIPK3. RCC4 cells were
transfected with either Lamin- or RIPK3-siRNA and analyzed for levels of RIPK3 over 2 days. (D) Clonogenic survival assay showing Nec1 pretreatment
or knockdown of essential necroptosis protein RIPK3 enhanced survival in the combination of CQ and CCI-779 as compared to cells without Nec1 or
with siRNA control siLamin.
doi:10.1371/journal.pone.0041831.g003
Targeting mTOR and Autophagy in Cancer
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41831
Figure 4. Mitochondrial ROS production causes cell death with coordinate mTOR and autophagy inhibition. (A) Mean ROS levels in
RCC4, untreated, CQ, CCI-779, or combination of CQ and CCI-779 after 6 hours by flow-cytometry using the ROS sensor DCF-DA
(*p = 0.003,**p = 0.004). (B) Viability graph of RCC4 cells after 18 hours with 40 mM CQ 40 mM CCI-779, 4 nM bafilomycin A1 (BAF) or combination
of CQ with CCI-779 or BAF. Cell death is prevented with the addition of 5 mM n-acetyl-cysteine (NAC) or 8 mM methyl-pyruvate (MP)
(*p = 0.004,**p = 0.002,+p=0.0003,++p= 0.0002). (C) Clonogenic survival assay of B. (D) Heat map showing relative pool sizes of TCA cycle
intermediates measured by LC-MS after 3 hour drug incubation. RCC4 cells with CCI-779 and CQ plus CCI-779 showed accumulation of
phosphoenolpyruvate (PEP) and a depletion of pyruvate (*p =,0.05). (E) Oxygen consumption rate (OCR) of RCC4 cells with DMEM control, 40 mM
CCI-779, CCI-779+5 mM NAC or CCI-779+8 mM MP after a 3 hour drug incubation (*p = 0.002,**p= 0.012). (F) RCC4 cells were stained with the
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suggesting that Nrf2 might be constitutively active, which was not
altered by CQ (Figure 5A). This is consistent with expression of
endogenous p62 that is bound to Keap1 (Figure 5C). CCI-779
alone and in combination with CQ suppressed nuclear transloca-
tion of RFP-Nrf2 (Figure 5A) and endogenous Nrf2 (Figure S6).
CCI-779 upregulated Nrf2 and p62 and dowregulated Keap1
(Figure 5B), suggesting that CCI-779 relieved Nrf2 from Keap1 by
upregulating p62, but also blocked Nrf2 nuclear translocation and
activation of the antioxidant response. Endogenous p62 and
Keap1 co-immunoprecipitated when mTOR was inhibited,
whereas Nrf2 and Keap1 did not (Figure 5C). Knockdown of
Keap1 induced Nrf2 accumulation and rescued cell viability and
clonogenic survival to subsequent CCI-779 and CQ treatment
(Figure 5D–F). This suggests that Nrf2 was active in RCC4 cells
due to p62 inactivation of Keap1, but that mTOR inhibition
prevents Nrf2 nuclear translocation and antioxidant defense,
creating the need for autophagy to mitigate ROS.
To determine the transcriptional activity of Nrf2, a firefly
luciferase reporter gene activity assay for the Nrf2 target gene Nqo1
was performed. Under normal growth conditions, Nqo1 activity
was high and this was repressed by CCI-779 and CCI-779 plus
CQ (Figure 5G). Similarly, Nqo1 mRNA (Figure 5H) and protein
levels (Figure 5I) were decreased by CCI-779 (12 hours). Levels of
Nqo11 mRNA went back up at 16 hours, presumably due to high
levels of ROS production at this time, Nrf2-independent activation
or activation of the mTOR negative feedback loop as evident by
phosphorylation of S6 (Figure 5B).
Inhibition of Nrf2 nuclear localization is caused by Gsk3b
phosphorylation [50], and CCI-779 suppressed phosphorylation of
Gsk3b on serine 9, indicative of activation (Figure 5B). Pretreatment
with a Gsk3b inhibitor partially rescued the block to Nrf2 nuclear
localization caused by CCI-779 (Figure 5J) and clonogenic survival
to CCI-779 and CQ (Figure 5K–L). Thus, mTOR inhibition
suppresses antioxidant defense, which is compensated for by
elimination of RIPKs and induction of autophagy. CQ blocks
autophagy and RIPK degradation, causing the persistence of ROS-
producing mitochondria, RIPK activation, and necroptosis.
Discussion
RCC is a disease with high mortality and allosteric mTOR
inhibitors have efficacy but are not curative [22,23]. Strategies
being implemented to improve outcome are combining rapalogs
with inhibitors targeting other pathways activated in RCC, such as
the VEGF pathway [51] or mTOR negative feedback [52].
Alternatively, if autophagy activation by mTOR inhibitors
promotes tumor cell survival, then therapeutic strategies to block
autophagy downstream of mTOR are warranted [15,16].
To establish if autophagy suppression improves anti-cancer
activity of mTOR inhibitors, we determined the functional role of
autophagy activation by rapalogs and that autophagy inhibition
enhanced the anti-tumor activity. Genetic or pharmacologic
autophagy suppression increased the cytotoxicity of CCI-779,
supporting a pro-survival role for autophagy. These findings
demonstrate the utility of coordinate mTOR and autophagy
inhibition.
It has become apparent that many aggressive cancers have
upregulated autophagy and are dependent on autophagy for
survival [11]. Autophagy in Ras-driven cancers and BCR-Abl-
driven leukemias is required for survival [4,26,29,33]. Although
the mechanism of autophagy addiction is not yet known, evidence
suggests that autophagy supplies mitochondrial substrates to
sustain the TCA cycle and respiration, without which mitochon-
dria malfunction, causing an energy crisis and cell death [4,29].
Although human RCC does not typically have Ras mutations, loss
of PTEN activates Ras effector pathways. Consistent with
autophagy addiction, RCC cell lines have high basal autophagy
and are dependent on autophagy for growth.
CQ and HCQ interfere with lysosome function, blocking the
degradation of the products of autophagy [53]. Although CQ can
have other activities, it is clear that CQ blocks autophagic flux and
enhances cytotoxicity of CCI-779, and that knockdown of Atg7
acted similarly. This suggests that inhibition of autophagy is
effective at sensitizing RCC cells to mTOR inhibition. CQ or
genetic inhibition of autophagy also sensitizes cancer cells to
cancer therapeutics, although the mechanisms are not known.
These include the proteasome inhibitor bortezomib (Velcade)
[6,10,54], alkylating agents [24], imantinib (Gleevec) [55], mTOR
inhibitors [30] and AKT inhibitors [28,56]. In contrast, in some
settings excessive autophagy is associated with cell death, and
small molecules have been identified that promote this form of cell
death specifically in VHL-negative RCC cell lines [57,58]. It will
be of interest to establish the mechanism by which excessive
autophagy stimulation may lead to cell death as well as to exploit
the utility of autophagy inhibitors to promote cell death.
In most cases, including mammalian development, autophagy
promotes survival [1]. Rare circumstances where autophagy
inhibition promotes survival may be due to upregulation of p62
and activation of Nrf2 [11]. Autophagy can prevent apoptosis,
necrosis [14,59], and now also necroptosis. Necroptosis is a
specialized form of programmed necrosis that must be inactivated
to prevent embryonic lethality [60,61,62]. Necroptosis is also part
of host defense against virus infection [63,64,65]. We have
delineated here that necroptosis is induced by mTOR inhibition,
mitochondrial respiration and RIPKs, when antioxidant defense
by Nrf2 and mitophagy are blocked. How RIPKs are activated is
not clear, but they may be sensors for mitochondrial distress such
as substrate limitation either upstream or downstream of ROS.
Autophagy-supplied mitochondrial substrates may preserve nor-
mal mitochondrial function while eliminating RIPKs through the
ubiquitin proteasome system, and distressed mitochondria through
mitophagy, enabling survival to mTOR inhibition. Independent of
the mechanism of RIPK activation, these findings demonstrate
that necroptosis is relevant for cancer therapy, as emerging
evidence suggests [66,67]. It will be important to establish if
necroptosis can be exploited, as the apoptosis pathway has been
[68], for the development of targeted cancer therapeutics.
A key determinant of mTOR inhibition-triggered necroptosis
was the blockade of Nrf2 nuclear translocation and antioxidant
mitochondrial potential-dependent dye Mitotracker Red and Tom20 after 3 hours of drug incubation. Scale bar = 10 microns. (G) RCC4 cells
expressing m-cherry-Parkin. Levels of mitophagy were quantitated after a 9 hour drug treatment by counting the percent of cells with punctuate m-
cherry-Parkin expression. Scale bar = 10 microns. % colocalization of mc-Parkin and Tom 20 +/2 S.D. shown as yellow numbers. (H) CCI-779 induces
mitophagy (38%,*p= 9.5261026). Levels of mitophagy are enhanced in the combination of CQ and CCI-779 (60%,**3.75261025). (I) RCC4 cells
pretreated for one hour with 10 mM CCCP followed by addition of CQ, CCI-779 or combination of CQ and CCI-779 to the media with and without
CCCP (*p= 0.002). (J) CCCP enhanced clonogenic survival of cells treated with the combination of CQ and CCI-779 for 18 hours. (K) Western blots
showing loss of RIPK1, RIPK3 and the mitochondrial marker Tom20 with CCI-779 at 12 hours, which is blocked by combination of CQ and CCI-779 as
well as cleavage of the mitochondrial marker Opa1. (L) Western blot showing RIPK1 and RIPK3 degradation is prevented by 100 nm epoxomicin.
doi:10.1371/journal.pone.0041831.g004
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defense. There were no deleterious consequences to mTOR
inhibition alone and blockade of Nrf2 because of elimination of
RIPKs and stimulation of mitophagy to promote elimination of
ROS-producing mitochondria (Figure 6). CQ alone prevents
mitophagy, but active Nrf2 was sufficient to manage the additional
ROS load. With mitophagy blocked, the resulting persistence of
ROS-producing mitochondria and RIPKs was lethal when
mTOR inhibition prevented Nrf2 activation (Figure 6). This
Figure 5. mTOR inhibition blocked Nrf2 nuclear translocation and anti-oxidant defense creating dependency on autophagy for
survival. (A) Ectopic expression of Nrf2 (red) and nuclear staining with Dapi (blue) after a 6 hour drug incubation. Yellow numbers represent the
percent of cells with nuclear Nrf2 +/2 the standard deviation. Scale bar = 10 mM. (B) Western blot time course of CCI-779 treated RCC4 cells. Nrf2 and
p62 were induced with CCI-779 treatment, while Keap1 levels go down. S6 lost phosphorylation after 1 hour of CCI-779 treatment, while total S6
remained the same. Akt lost phosphorylation at serine 473 after 9 hours of CCI-779 treatment. Gsk3b lost its phosphorylation after 1 hour of CCI-779
incubation. (C) Immunoprecipitation of IGG control antibody, Nrf2, and Keap1 after 0, 3, 6 hours CCI-779 incubation. Nrf2 and Keap1 did not co-
immunoprecipitate while p62 co-immunoprecipitates with Keap1. (D) Western blot of siRNA knockdown of Keap1. RCC4 cells were transfected with
either Lamin or Keap1 siRNA and analyzed for levels of Keap1. Knockdown of Keap1 induced Nrf2. (E) Viability graph showing knockdown of Keap1
rescued cell death induced by CQ and CCI-779 combination as compared to the Lamin control after 18 hours. (*p = 0.003) (F) Clonogenic survival
assay of RCC4 cells with RNA knockdown of Keap1 or Lamin control. (G) CCI-779 regulated transcriptional activity of Nrf2. RCC4 cells were transfected
with the NQO1-ARE promoter firefly luciferase and Renilla luciferase as a control. Relative NQO1 mRNA level was measured. (*p = 2.35361025) (H) CCI-
779 regulated mRNA level and protein level (I) of the Nrf2 target gene Nqo1. (Western blot of Nqo1). (*p = 0.003). (J) Localization of ectopically
expressed Nrf2-RFP. CCI-779 caused exclusion Nrf2 from the nucleus. Pretreatment with a Gsk3b inhibitor restored nuclear localization of Nrf2. Yellow
numbers represent % nuclear localization +/2 S.D. (K) Clonogenic survival assay showing enhanced survival of CQ and CCI-779 treated cells when
treated in combination with either 2 or 5 mM Gsk3b inhibitor. (L) Quantitation of colonies formed after the combination of CQ and CCI-779 with the
Gsk3b inhibitor (*p = 1.0161024).
doi:10.1371/journal.pone.0041831.g005
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critical balance between Nrf2 antioxidant defense and mitophagy
to manage ROS and RIPKs is uncoupled by combining CQ with
mTOR inhibition (Figure 6). In RCC, p62 is expressed and bound
to Keap1 enabling Nrf2 activation. Mutations activating Nrf2 or
inactivating the inhibitor of Nrf2, Keap1, are found in human
cancers [46,69]. Thus, p62 expression similar to Nrf2 activation or
Keap1 inactivation may enhance antioxidant defense and cancer
cell survival. It is intriguing to speculate that cancers with Nrf2
pathway activation may be vulnerable to coordinate mTOR and
autophagy inhibition and RIPK- and ROS-mediated necroptosis,
and that inactivation of RIPKs and necroptosis is a mechanism of
resistance to cancer therapy.
Materials and Methods
Ethics statement
Tumor assays in mice were performed using Institutional
Animal Care and Use approved protocols and was approved by
IACUC committee members at the University of Medicine and
Dentistry of New Jersey (UMDNJ). Tumor assays performed in
this manuscript were approved under the protocol, I10-064-8,
‘‘Use of Mice for Tumorigenicity.’’ Mice were monitored for
overall health in response to drug treatment and sacrificed when
tumor size exceeded 400 mm3. All efforts were made to minimize
suffering during the experiment. Full details and experimental
conditions are listed below.
Cell lines and culture conditions
RCC4, UMRC2, UOK101, ACHN, 786O and A498 were
cultured in DMEM without sodium pyruvate (Invitrogen), 10%
FBS, and 1% Penn/Strep at 37uC and 5% CO2. 769P was cultured
in RPMI media (Invitrogen) with 10% FBS, 1% Penn/Strep at
37uC and 5% CO2. All RCC cell lines were obtained from Dr.
William Kaelin. All RCC cell lines were originally purchased from
the ATCC except UOK101 [70] and UMRC2 [71]. I2.1 cells were
cultured in RPMI media with 10% FBS, 1% Penn/Strep and were
purchased from the ATCC. For viability assays, cells were collected
and counted by trypan blue exclusion. CQ and CCI-779 were used
at 40 mM for all in vitro experiments unless otherwise noted. For
clonogenic survival assays, cells were subjected to 18 hour drug
treatments (unless otherwise stated) and then allowed to recover in
normal media for 5 days. Colonies were fixed in methanol, stained
with Geimsa (Sigma), and photographed.
Drug administration in mouse allografts
Tumor assays were performed using Institutional Animal Care
and Use approved protocols. RCC4 cells (107 cells/injection) were
inoculated subcutaneously to form tumors. Mice with tumors
(150 mm3) assorted to four groups (5 mice/group). Vehicle or CQ
(65 mg/kg/d, 7 d/week, 3 cycles) or CCI-779 (20 mg/kg/d, 5 d/
week, 3 cycles) alone or in combination was administrated
intraperitoneally. CCI-779 was prepared in the provided diluent
and further diluted in PBS. CQ was prepared in PBS.
Western blotting, immunofluorescence, and electron
microscopy
Western blotting and immunofluorescence were performed as
previously described [72]. For fluorescent visualization of
mCherry-Parkin localization, cells were plated on cover-slips,
subjected to drug incubation and fixed in 4% paraformaldehyde
(mCherry-Parkin) for 15 min at room temperature. For fluores-
cent visualization of RFP-NRF2, cells were plated on cover-slips,
subjected to drug incubation and fixed in methanol for 10 minutes
at 220uC. For LC3 and Nrf2 immunostaining cells with fixed in
methanol for 20 min at 220uC and stained with primary antibody
(LC3 antibody, Novus Biologicals, NB600-1384, 1:2000) or NRF2,
Santa Cruz, sc.13032 1:250) for 2 hours at 37uC followed by
FITC or TRITC tagged anti-rabbit (Jackson Immuno Research,
1:50 dilution). For mitochondrial imaging by EM, cells were fixed
in 0.1 M cacodylate buffer with 2.5% glutaraldehyde, 4%
paraformaldehyde, and 8 mM CaCl2 and analyzed by a JOEL
1200EX electron microscope as described previously [14].
Autophagy and mitophagy assessment
For quantification of autophagy levels, cells were immuno-
stained with LC3 antibody as described above. Autophagy levels
were quantitated by scoring a minimum of 200 cells in three
replicate experiments. A cell with more than 20 LC3 puncta was
defined as positive for autophagy. Images were analyzed at 10006
magnification. The percentage of cells with mCherry-Parkin
translocation was quantified by determining the number of cells
displaying punctate fluorescence out of a population of 200
fluorescent cells replicated in three independent experiments.
Figure 6. Model depicting mechanism of necroptosis induction
by mTOR and autophagy inhibition. Renal carcinoma cells have
activated mTOR, Nrf2 antioxidant defense and autophagy under basal
conditions sufficient to manage ROS and survive. Autophagy inhibition
with CQ blocks clearance of damaged mitochondrial through mito-
phagy. ROS is mitigated through the Nrf2 antioxidant defense pathway.
mTOR inhibition promotes respiration and inhibits Nrf2 antioxidant
defense. RIPKs are degraded by the ubiquitin proteasome system and
damaged mitochondrial are cleared by mitophagy to maintain ROS
homeostasis and cell survival. Pharmacological inhibition of both
autophagy with CQ and mTOR with CCI-779 causes loss of antioxidant
defense via Nrf2 and persistence of RIPKs and mitochondria leading to
RIPK activation and ROS-mediated cell death by necroptosis.
doi:10.1371/journal.pone.0041831.g006
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ROS assays
ROS levels were determined by washing proliferating cells once
with Hanks balanced salt solution (HBSS) (Invitrogen) and
incubating in 10 mM 29-79-dichlorodihydrofluorescene diacetate
(DCF-DA, Molecular Probes, Invitrogen) in pre-warmed HBSS
for 15 min at 37uC followed by measurement of mean fluores-
cence by flow-cytometry (FC500; Beckman Coulter). Three
independent experiments were performed analyzing 10,000 cells
(per genotype) in each experiment. For visualization of ROS by
fluorescence, cells were plated on coverslips and subjected to drug
incubation. Following drug incubation 5 mM MitoSOXTM Red
superoxide indicator (Molecular Probes, Invitrogen) was added to
the media and incubated 10 minutes. Cells were washed with PBS
and imaged at 6006magnification.
RNA interference
RCC4 cells were transfected with siGENOME SMARTpool
siRNA targeted against human RIPK3 (NM_006871), Keap1
(NM_012289) or Lamin A/C control siRNA (Dharmacon
Research, Chicago, IL; M-047628-00-0010) using lipofectomine
transfection reagent (Invitrogen). 24, 48 or 72 hours post-
transfection, cells were incubated with drugs and viability was
assessed by trypan blue (Invitrogen) exclusion or by clonogenic
assay. Total protein was isolated in parallel and analyzed by
Western blotting to assess knock-down of target genes.
For shRNA knockdown of Atg7, pLKO.1-derived vectors with
shRNAs targeting Atg7 were purchased from Sigma-Aldrich
(TRCN0000007584, and TRCN0000007587). Control shRNAs
against RFP and Luciferase were generously provided by the
Broad Institute. Virus was produced using a second-generation
packaging system in 293T cells as described [73].
Luciferase reporter gene assay
Luciferase reporter assays were performed as described
previously [49]. Briefly, RCC4 cells were transiently transfected
with 1.6 mg of the Nqo1 ARE luciferase and 0.01 mg Renilla
luciferase control (hRluc/TK) plasmids. Approximately 24 hours
post transfection, cells were treated with CQ, CCI-779 or
combination of CQ and CCI-779 for 12 hours. Relative luciferase
activities were calculated using Promega Dual Luciferase kit
(Promega Corporation, WI) and a TD 20/20 luminometer
(Turner Designs, Sunnyvale, CA) and normalized to Renilla
luciferase values.
mRNA extraction and real-time qRT-PCR
Total mRNA was extracted using TRIzol (Invitrogen) according
to the manufacturer’s instructions. Using equal amounts of mRNA
and the Transcriptor First Strand cDNA synthesis kit (Roche),
cDNA was generated and used for real-time quantitative reverse
transcription-PCR (qRT-PCR). The TaqMan probes were
obtained from the universal probe library (Roche): hNQO1,
no. 87; and hGAPDH (glyceraldehyde-3-phosphate dehydroge-
nase), no. 25. Forward and reverse primers for hNQO1, and
hGAPDH were synthesized by Integrated DNA Technologies:
sequences are as follows: hNQO1, ATGTATGACAAAG-
GACCCTTCC (forward) and TCCCTTGCAGAGAGTA-
CATGG (reverse); and hGAPDH, CTGACTTCAACAGCGA-
CACC (forward) and TGCTGTAGCCAAATTCGTTGT
(reverse). Real-time PCR was performed as followed: one cycle
of predenaturation (95uC for 5 min), 45 cycles of amplification
(95uC for 10 s and 60uC for 20 s), and a cooling program of 50uC
for 30 s. Reactions were done in triplicate, and the experiment was
repeated three times. The data were expressed as relative mRNA
levels and normalized to GAPDH.
Mitochondrial membrane potential assay
RCC4 cells were seeded at 1.56105 cells per cell in a 12-well
plate. Cells were treated with CQ, CCI-779 or combination for
3 hours. Following drug treatment, cells were stained with 50 nM
Mitotracker Red (Molecular Probes/Invitrogen) for 20 minutes at
37uC in DMEM with 10% FBS and 1%P/S. Cells were washed
for 15 minutes in DMEM and visualized (data not shown) or fixed
in 4% PFA for 15 minutes at room temperature. Cells were then
stained with Tom20 as described above.
OCR rate measurement
OCR rates were measured using Seahorse Biosciences extra-
cellular flux analyzer (XF24-3). Cells were seeded at 7.56104 cells
per well (0.32 cm2) in XF24 plates in 250 mL of DMEM (10%
FBS, 1% Pen-Strep) and incubated for 20–24 h at 38.5uC and
8.5% CO2 prior to XF assay and OCR measurements were made
as described previously [42].
Metabolomic analysis by LC-MS
Pool size measurements in major TCA cycle intermediates by
LC-MS were performed as described previously [74]. Briefly, cells
were cultured in complete media (DMEM, 10% dialyzed FBS, 1%
Pen-Strep) for 20–24 h, after which media was replaced with
DMEM containing drugs. Metabolism was quenched by removing
the media and adding methanol:water (80:20) at 280uC.
Extracted metabolites were dried under nitrogen flow, reconsti-
tuted in water, and measured by LC-MS. Metabolites were
identified by accurate mass (,5 ppm deviation, Exactive) or
characteristic fragmentation product (triple quads), in combination
with retention time matched to validated standards, using in-house
software. Peak intensity data was further analyzed using Excel and
MatLab. Metabolite ion count in each replicate sample was
normalized to the cell number and the normalized ion counts were
expressed as fold change normalized to the untreated control. To
find statistical significance fold change ratios were log2 trans-
formed, and p-value calculated using two-tailed distribution. A p-
value,0.05 was considered statistically significant. Major TCA
metabolites were selected and cell number-normalized pool sizes
were calculated as an average of three replicate measurements.
Antibodies and chemicals
The following antibodies were used: Actin, RIPK3, Atg7
(Sigma); LC3 (Novus), p62 (Biomol and a rabbit polyclonal
antibody [4]); active caspase-3 (Asp175), S6, phospho-S6 (ser 235/
236), AKT, phospho-AKT 473, phospho-GSK3b (ser 9), GSK3b
(Cell Signaling), Nrf2 (H300), Keap1 (E20), Tom20 (F10) and
Nqo1 (Santa Cruz), RIPK1, Opa1 (BD Transduction). The
following chemicals were obtained as follows: CCI-779 (Wyeth
and Sigma), chloroquine disulfate salt (CQ), bafilomycin A1,
Necrostatin-1, N-acetyl-cysteine, N-acetyl-alanine, CCCP, and
methyl-pyruvate (Sigma), Mitotracker Red FM (Invitrogen),
Torin1 (generously provided by Nathanael S. Gray), and the
Gsk3b Inhibitor XII (TWS119) (EMD Chemicals).
Statistics
Mean 6 standard deviation (s.d.) was presented, except in
Figure 2D, where mean 6 standard error was presented. Data
shown are the results of three independent experiments. P values
were calculated using a paired two-tailed students t-test. P,0.05
was considered significant.
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Supporting Information
Figure S1 Renal carcinoma cell lines have high basal
autophagy and are sensitive to the combination of CQ
and CCI-779. (Related to Figure 1) (A) Endogenous LC3
immunostaining in human RCC cell lines (hRCCs). hRCCs were
left untreated or treated with 40 mM CQ for 3 hours. Levels of
autophagy were quantitated by counting the % of cells with more
than 20 LC3 puncta as positive. All hRCCs have high basal
autophagy and show 100% punctation with treated with CQ
indicating high autophagic flux. Scale bar = 10 mm. (B) Represen-
tative stills from Movies S1, S2, S3, S4, S5, S6, S7, S8, S9, S10,
S11, S12, S13, S14, S15, S16. RCC4 and A498, with and without
VHL, were incubated with 40 mM CCI-779, 40 mM CQ or
combination of CQ and CCI-779 for 18 hours. Combination of
CQ and CCI-779 dramatically induced cell death in RCC cells.
(TIF)
Figure S2 Autophagy and mTOR inhibition induces cell
death. (Related to Figure 2) (A) Representative images of
Fig. 2A and B after 7 days of drug incubation demonstrating
toxicity of 20 mM CQ and 20 mM CCI-779 or 20 mM CQ and
250 nM Torin1. Scale bar = 50 microns. (B) Representative
images of Fig. 2D showing RCC4 cells with control knockdown
(shRfp, shLuc) or knockdown of Atg7 (shAtg7#1,2). Atg7
knockdown sensitized RCC4 to 40 mM CCI-779. Scale bar = 50 -
microns.
(TIF)
Figure S3 Autophagy and mTOR inhibition induces
necroptosis. (Related to Figure 3) (A) Western blot for
cleaved caspase-3 in RCC4 treated with CQ, CCI-779 and
combination of 40 mM CQ and 40 mM CCI-779 at 16 hrs. As a
control RCC4 cells were treated with 4 mM staurosporine for
10 hours. (B) Clonogenic survival assay showing that the pan-
caspase inhibitor Q-VD-OPh does not rescue cell death induced
by CQ and CCI. RCC4 was pretreated with 20 mM Q-VD-OPh
for 1 hour followed by the addition of 40 mMCQ and 40 mMCCI
to the media. After an 18 hour drug treatment media was changed
to normal growth media and cells were allowed to recover for 5
days. (C) Representative images of Fig. 3B. Knockdown of RIP3K
in RCC4 rescues cell death induced by 40 mM CQ and 40 mM
CCI as compared to Lamin control knockdown. Scale
bar = 50 mM. (D) Western blot showing that RCC4 cells do not
cleave Caspase-8 in response to 40 mM CQ and 40 mM CCI in
comparison to control treated with 100 nM TNF-a and 10 mg/ml
cycloheximide. (E) RCC4 and I2.1 (Fadd2/2 Jurkat cells) were
treated with 100 nM TNF-a and 50 mM Z-VAD-FMK. TNF-a
alone induced necroptosis in I2.1 cells. RCC4 remained viable
even in the presence of Z-VAD-FMK.
(TIF)
Figure S4 Mitochondrial ROS production causes cell
death that is rescued by NAC and methyl-pyruvate.
(Related to Figure 4) (A) MitoSox Red superoxide indicator
staining of RCC4 cells. 40 mM CCI-779 and combination of
40 mM CQ and 40 mM CCI-779 had high levels of ROS as
indicated by MitoSox Red fluorescence after a 6 hour drug
incubation. Scale bar = 10 mM. (B) Representative images of
Fig. 4B. RCC4 was treated with 4 nM Bafilomycin A1, 40 mM
CQ, 40 mMCCI-779 or combination of Bafilomycin A1 and CCI-
779 or CQ and CCI-779. The combination of Bafilomycin A1
(BAF) or CQ with CCI-779 induces cell death that is rescue with
5 mM n-acetyl-cysteine (NAC) or 8 mM methyl-pyruvate (MP).
Scale bar = 50 mM. (C) Clonogenic survival assay. Combination of
BAF and CCI-779 induces cell death that is rescued by NAC and
MP. (D) Cell death induced by combination of CQ and CCI-779
is rescued by NAC but not n-acetyl-alanine (NAA).
(*p = 2.0161024) (E) Clonogenic assay of treatment shown in D.
(F). Representative photos of D. Scale Bar = 50 mM.
(TIF)
Figure S5 Mitochondrial are required for necroptosis.
(Related to Figure 4) (A) Electron micrographs of RCC4
treated with 40 mM CQ, 40 mM CCI-779, or combination of CQ
and CCI-779. Mitochondrial appear fragmented with CCI-779 or
combination of CQ and CCI-779. (B) Representative images of
Fig. 4I. 10 mM CCCP rescued cell death induced by the
combination of CQ and CCI-779 in RCC4 cells. Scale
Bar = 50 mM. (C) Mitochondrial potential assay showing loss of
mitotracker red and membrane potential as compared to total
mitochondria (Tom20) after a 6 hour incubation with 10 mM
CCCP. Scale Bar = 10 mM. (D) CCCP caused m-cherry-Parkin to
translocate to the mitochondria. Scale Bar = 10 mM.
(TIF)
Figure S6 CCI-779 blocks nuclear translocation if Nrf2.
(Related to Figure 5) Endogenous staining of Nrf2 in RCC4
cells after a 6 hour drug incubation. Nrf2 is predominately nuclear
when left untreated or with 40 mM CQ. Nrf2 is excluded from the
nuclease with 40 mM CCI-779 or combination of CQ and CCI-
779. Scale bar = 10 mM.
(TIF)
Movie S1 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (with VHL expression) cell line under normal
growth conditions, related to Fig. S1B.
(AVI)
Movie S2 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (with VHL) cell line with 40 mMCQ, related to Fig.
S1B.
(AVI)
Movie S3 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (with VHL) cell line with 40 mM CCI-779, related
to Fig. S1B.
(AVI)
Movie S4 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (with VHL) cell line with combination of 40 mM
CQ and 40 mM CCI-779, related to Fig. S1B.
(AVI)
Movie S5 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (without VHL) cell line under normal growth
conditions, related to Fig. S1B.
(AVI)
Movie S6 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (without VHL) cell line with 40 mM CQ, related to
Fig. S1B.
(AVI)
Movie S7 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (without VHL) cell with 40 mMCCI-779, related to
Fig. S1B.
(AVI)
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Movie S8 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human RCC4 (without VHL) cell line with combination of 40 mM
CQ and 40 mM CCI-779, related to Fig. S1B.
(AVI)
Movie S9 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (with VHL expression) cell line under normal growth
conditions, related to Fig. S1B.
(AVI)
Movie S10 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (with VHL) cell with 40 mMCQ, related to Fig. S1B.
(AVI)
Movie S11 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (with VHL) cell with 40 mMCCI-779, related to Fig.
S1B.
(AVI)
Movie S12 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (with VHL) cell line with combination of 40 mM CQ
and 40 mM CCI-779, related to Fig. S1B.
(AVI)
Movie S13 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (without VHL) cell line under normal growth
conditions, Fig. S1B.
(AVI)
Movie S14 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (without VHL) cell line with 40 mM CQ, related to
Fig. S1B.
(AVI)
Movie S15 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (without VHL) cell with 40 mM CCI-779, related to
Fig. S1B.
(AVI)
Movie S16 CQ synergizes with CCI-779 to promote cell
death in human RCC cell lines. Time-lapse microscopy of
human A498 (without VHL) cell line with 40 mM CQ and 40 mM
CCI-779 in combination, related to Fig. S1B. Time-lapse
microscopy of human RCC4 (Movies S1, S2, S3, S4, S5, S6,
S7, S8) and A498 (Movies S9, S10, S11, S12, S13, S14, S15, S16)
cell lines under normal growth conditions and in the presence of
CQ, the mTOR inhibitor CCI-779, or combination of CQ and
CCI-779. Cells were plated on culture dishes and placed in a time-
lapse environmental chamber of normal growth conditions.
Images were acquired with an Olympus IX71 inverted microscope
every 10 minutes for 30 hours. Time-lapse images were converted
to movies using ImagePro Plus software (Degenhardt et al., 2006).
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